Kennedy-Martin Tessa, Curtis Sarah, Faries Douglas, Robinson Susan, Johnston Joseph
Kennedy-Martin Health Outcomes Ltd, 3rd Floor, Queensberry House, 106 Queens Road, Brighton, BN1 3XF, UK.
Eli Lilly and Company, Indianapolis, Indiana, USA.
Trials. 2015 Nov 3;16:495. doi: 10.1186/s13063-015-1023-4.
Randomized controlled trials (RCTs) are conducted under idealized and rigorously controlled conditions that may compromise their external validity. A literature review was conducted of published English language articles that reported the findings of studies assessing external validity by a comparison of the patient sample included in RCTs reporting on pharmaceutical interventions with patients from everyday clinical practice. The review focused on publications in the fields of cardiology, mental health, and oncology. A range of databases were interrogated (MEDLINE; EMBASE; Science Citation Index; Cochrane Methodology Register). Double-abstract review and data extraction were performed as per protocol specifications. Out of 5,456 de-duplicated abstracts, 52 studies met the inclusion criteria (cardiology, n = 20; mental health, n = 17; oncology, n = 15). Studies either performed an analysis of the baseline characteristics (demographic, socioeconomic, and clinical parameters) of RCT-enrolled patients compared with a real-world population, or assessed the proportion of real-world patients who would have been eligible for RCT inclusion following the application of RCT inclusion/exclusion criteria. Many of the included studies concluded that RCT samples are highly selected and have a lower risk profile than real-world populations, with the frequent exclusion of elderly patients and patients with co-morbidities. Calculation of ineligibility rates in individual studies showed that a high proportion of the general disease population was often excluded from trials. The majority of studies (n = 37 [71.2 %]) explicitly concluded that RCT samples were not broadly representative of real-world patients and that this may limit the external validity of the RCT. Authors made a number of recommendations to improve external validity. Findings from this review indicate that there is a need to improve the external validity of RCTs such that physicians treating patients in real-world settings have the appropriate evidence on which to base their clinical decisions. This goal could be achieved by trial design modification to include a more representative patient sample and by supplementing RCT evidence with data generated from observational studies. In general, a thoughtful approach to clinical evidence generation is required in which the trade-offs between internal and external validity are considered in a holistic and balanced manner.
随机对照试验(RCTs)是在理想化且严格控制的条件下进行的,这可能会损害其外部有效性。我们对已发表的英文文章进行了文献综述,这些文章通过比较报告药物干预的随机对照试验中纳入的患者样本与日常临床实践中的患者,来评估研究的外部有效性。该综述聚焦于心脏病学、心理健康和肿瘤学领域的出版物。我们检索了一系列数据库(MEDLINE;EMBASE;科学引文索引;Cochrane方法学注册库)。按照方案规范进行了双摘要评审和数据提取。在5456篇去重摘要中,有52项研究符合纳入标准(心脏病学,n = 20;心理健康,n = 17;肿瘤学,n = 15)。这些研究要么对随机对照试验纳入患者的基线特征(人口统计学、社会经济和临床参数)与真实世界人群进行了分析,要么评估了在应用随机对照试验纳入/排除标准后符合随机对照试验纳入条件的真实世界患者的比例。许多纳入研究得出结论,随机对照试验样本经过高度筛选,与真实世界人群相比风险特征较低,老年患者和合并症患者经常被排除在外。个别研究中不符合纳入标准率的计算表明,很大比例的一般疾病人群通常被排除在试验之外。大多数研究(n = 37 [71.2%])明确得出结论,随机对照试验样本不能广泛代表真实世界患者,这可能会限制随机对照试验的外部有效性。作者提出了一些提高外部有效性的建议。该综述的结果表明,有必要提高随机对照试验的外部有效性,以便在真实世界环境中治疗患者的医生有适当的证据来做出临床决策。这一目标可以通过修改试验设计以纳入更具代表性的患者样本,以及用观察性研究产生的数据补充随机对照试验证据来实现。总体而言,需要一种深思熟虑的临床证据生成方法,其中要全面、平衡地考虑内部有效性和外部有效性之间的权衡。